The EGFR-HER2 module: A stem cell approach to understanding a prime target and driver of solid tumors

Oncogene

Volumn 35, Issue 23, 2016, Pages 2949-2960

  Schneider, M R ^a   Yarden, Y ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NEU DIFFERENTIATION FACTOR; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

BRAIN TUMOR; CAENORHABDITIS ELEGANS; CANCER STEM CELL; CELL DEDIFFERENTIATION; CELL DIVISION; CELL REGENERATION; HUMAN; INTESTINAL STEM CELL; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; ANIMAL; CARCINOMA; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; STEM CELL; TUMOR CELL LINE;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 84973916839     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.372     Document Type: Review

References (167)

1. Pellettieri J, Sanchez Alvarado A. Cell turnover and adult tissue homeostasis: from humans to planarians. Annu Rev Genet 2007; 41: 83-105.
2. Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015; 347: 78-81.
3. Blanpain C, Horsley V, Fuchs E. Epithelial stem cells: turning over new leaves. Cell 2007; 128: 445-458.
4. Hsu YC, Li L, Fuchs E. Emerging interactions between skin stem cells and their niches. Nat Med 2014; 20: 847-856.
5. Schneider MR, Schmidt-Ullrich R, Paus R. The hair follicle as a dynamic miniorgan. Curr Biol 2009; 19: R132-142.
6. Tashiro A, Sandler VM, Toni N, Zhao C, Gage FH. NMDA-receptor-mediated cell-specific integration of new neurons in adult dentate gyrus. Nature 2006; 442: 929-933.
7. Hennighausen L, Robinson GW. Information networks in the mammary gland. Nat Rev Mol Cell Biol 2005; 6: 715-725.
8. Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol 2005; 6: 328-340.
9. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72.
10. Grompe M. Liver stem cells, where art thou? Cell Stem Cell 2014; 15: 257-258.
11. Dor Y, Brown J, Martinez OI, Melton DA. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004; 429: 41-46.
12. Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, Jaworski M et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 2008; 135: 1118-1129.
13. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003-1007.
14. Doupe DP, Jones PH. Cycling progenitors maintain epithelia while diverse cell types contribute to repair. BioEssays 2013; 35: 443-451.
15. Sato T, van Es JH, Snippert HJ, Stange DE, Vries RG, van den Born M et al. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 2011; 469: 415-418.
16. Lim RW, Hauschka SD. A rapid decrease in epidermal growth factor-binding capacity accompanies the terminal differentiation of mouse myoblasts in vitro. J Cell Biol 1984; 98: 739-747.
17. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
18. Gupta BP, Hanna-Rose W, Sternberg PW. Morphogenesis of the vulva and the vulval-uterine connection. WormBook 2012. 1-20.
19. Sulston JE, White JG. Regulation and cell autonomy during postembryonic development of Caenorhabditis elegans. Dev Biol 1980; 78: 577-597.
20. Schweitzer R, Shilo BZ. A thousand and one roles for the Drosophila EGF receptor. Trends Genet 1997; 13: 191-196.
21. Yasugi T, Sugie A, Umetsu D, Tabata T. Coordinated sequential action of EGFR and Notch signaling pathways regulates proneural wave progression in the Drosophila optic lobe. Development 2010; 137: 3193-3203.
22. Morante J, Desplan C. The color-vision circuit in the medulla of Drosophila. Curr Biol 2008; 18: 553-565.
23. Kai T, Spradling A. Differentiating germ cells can revert into functional stem cells in Drosophila melanogaster ovaries. Nature 2004; 428: 564-569.
24. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999; 96: 4995-5000.
25. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA 2010; 107: 7692-7697.
26. Goldman R, Levy RB, Peles E, Yarden Y. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 1990; 29: 11024-11028.
27. Yarden Y, Schlessinger J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 1987; 26: 1443-1451.
28. Wada T, Qian XL, Greene MI. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 1990; 61: 1339-1347.
29. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12: 541-552.
30. Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J. A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem 2015; 84: 739-764.
31. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A. Heregulindependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 1995; 14: 4267-4275.
32. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 2011; 12: 104-117.
33. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009; 21: 177-184.
34. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F et al. A module of negative feedback regulators defines growth factor signaling. Nat Genet 2007; 39: 503-512.
35. Goh LK, Huang F, Kim W, Gygi S, Sorkin A. Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor. J Cell Biol 2010; 189: 871-883.
36. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999; 4: 1029-1040.
37. Zwang Y, Yarden Y. Systems biology of growth factor-induced receptor endocytosis. Traffic 2009; 10: 349-363.
38. Haglund K, Dikic I. The role of ubiquitylation in receptor endocytosis and endosomal sorting. J Cell Sci 2012; 125: 265-275.
39. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996; 15: 2452-2467.
40. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 1996; 271: 5251-5257.
41. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16: 5276-5287.
42. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: 1647-1655.
43. Schneider MR, Werner S, Paus R, Wolf E. Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology. Am J Pathol 2008; 173: 14-24.
44. Mann GB, Fowler KJ, Gabriel A, Nice EC, Williams RL, Dunn AR. Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 1993; 73: 249-261.
45. Fowler KJ, Walker F, Alexander W, Hibbs ML, Nice EC, Bohmer RM et al. A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. Proc Natl Acad Sci USA 1995; 92: 1465-1469.
46. Schneider MR. The magnificient seven: epidermal growth factor receptor ligands. Semin Cell Dev Biol 2014; 28: 1.
47. Luetteke NC, Qiu TH, Peiffer RL, Oliver P, Smithies O, Lee DC. TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell 1993; 73: 263-278.
48. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A et al. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 1999; 126: 2739-2750.
49. Troyer KL, Luetteke NC, Saxon ML, Qiu TH, Xian CJ, Lee DC. Growth retardation, duodenal lesions, and aberrant ileum architecture in triple null mice lacking EGF, amphiregulin, and TGF-alpha. Gastroenterology 2001; 121: 68-78.
50. Sibilia M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995; 269: 234-238.
51. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995; vol. 269: 230-234.
52. Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA, Werb Z et al. Nature 1995; 376: 337-341.
53. Sun Y, Goderie SK, Temple S. Asymmetric distribution of EGFR receptor during mitosis generates diverse CNS progenitor cells. Neuron 2005; 45: 873-886.
54. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, Holcmann M. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007; 75: 770-787.
55. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995; 378: 386-390.
56. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378: 394-398.
57. Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995; 378: 390-394.
58. Erickson SL, O'Shea KS, Ghaboosi N, Loverro L, Frantz G, Bauer M et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development 1997; 124: 4999-5011.
59. Riethmacher D, Sonnenberg-Riethmacher E, Brinkmann V, Yamaai T, Lewin GR, Birchmeier C. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature 1997; 389: 725-730.
60. Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C et al. Axonal neuregulin-1 regulates myelin sheath thickness. Science 2004; 304: 700-703.
61. Kitade M, Factor VM, Andersen JB, Tomokuni A, Kaji K, Akita H et al. Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling. Genes Dev 2013; 27: 1706-1717.
62. Desai TJ, Brownfield DG, Krasnow MA. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature 2014; 507: 190-194.
63. Krampera M, Pasini A, Rigo A, Scupoli MT, Tecchio C, Malpeli G et al. HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Blood 2005; 106: 59-66.
64. Genetos DC, Rao RR, Vidal MA. Betacellulin inhibits osteogenic differentiation and stimulates proliferation through HIF-1alpha. Cell Tissue Res 2010; 340: 81-89.
65. Tamama K, Fan VH, Griffith LG, Blair HC, Wells A. Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells. Stem Cells 2006; 24: 686-695.
66. Zhu J, Shimizu E, Zhang X, Partridge NC, Qin L. EGFR signaling suppresses osteoblast differentiation and inhibits expression of master osteoblastic transcription factors Runx2 and Osterix. J Cell Biochem 2011; 112: 1749-1760.
67. Doan PL, Himburg HA, Helms K, Russell JL, Fixsen E, Quarmyne M et al. Epidermal growth factor regulates hematopoietic regeneration after radiation injury. Nat Med 2013; 19: 295-304.
68. Nieto-Sampedro M, Gomez-Pinilla F, Knauer DJ, Broderick JT. Epidermal growth factor receptor immunoreactivity in rat brain astrocytes. Response to injury. Neurosci Lett 1988; 91: 276-282.
69. Aguirre A, Dupree JL, Mangin JM, Gallo V. A functional role for EGFR signaling in myelination and remyelination. Nat Neurosci 2007; 10: 990-1002.
70. Iyer R, Thames HD, Tealer JR, Mason KA, Evans SC. Effect of reduced EGFR function on the radiosensitivity and proliferative capacity of mouse jejunal crypt clonogens. Radiother Oncol 2004; 72: 283-289.
71. Clevers H, Batlle E. SnapShot: the intestinal crypt. Cell 2013; 152: e1192.
72. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 2004; 23: 3270-3281.
73. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL III. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 2004; 279: 47050-47056.
74. Wong VW, Stange DE, Page ME, Buczacki S, Wabik A, Itami S. Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nat Cell Biol 2012; 14: 401-408.
75. Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK et al. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 2012; 149: 146-158.
76. Marchbank T, Goodlad RA, Lee CY, Playford RJ. Luminal epidermal growth factor is trophic to the small intestine of parenterally fed rats. Clin Sci 1995; 89: 117-120.
77. Bashir O, Fitzgerald AJ, Berlanga-Acosta J, Playford RJ, Goodlad RA. Effect of epidermal growth factor administration on intestinal cell proliferation, crypt fission and polyp formation in multiple intestinal neoplasia (Min) mice. Clin Sci 2003; 105: 323-330.
78. Dahlhoff M, Horst D, Gerhard M, Kolligs FT, Wolf E, Schneider MR. Betacellulin stimulates growth of the mouse intestinal epithelium and increases adenoma multiplicity in Apc+/Min mice. FEBS Lett 2008; 582: 2911-2915.
79. van Es JH, Sato T, van de Wetering M, Lyubimova A, Nee AN, Gregorieff A et al. Dll1+ secretory progenitor cells revert to stem cells upon crypt damage. Nat Cell Biol 2012; 14: 1099-1104.
80. Fuentealba LC, Obernier K, Alvarez-Buylla A. Adult neural stem cells bridge their niche. Cell Stem Cell 2012; 10: 698-708.
81. Tong CK, Alvarez-Buylla A. SnapShot: adult neurogenesis in the V-SVZ. Neuron 2014; 81: e221.
82. Ponti G, Obernier K, Guinto C, Jose L, Bonfanti L, Alvarez-Buylla A. Cell cycle and lineage progression of neural progenitors in the ventricular-subventricular zones of adult mice. Proc Natl Acad Sci USA 2013; 110: E1045-E1054.
83. Doetsch F, Petreanu L, Caille I, Garcia-Verdugo JM, Alvarez-Buylla A. EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells. Neuron 2002; 36: 1021-1034.
84. Ninomiya M, Yamashita T, Araki N, Okano H, Sawamoto K. Enhanced neurogenesis in the ischemic striatum following EGF-induced expansion of transit-amplifying cells in the subventricular zone. Neurosci Lett 2006; 403: 63-67.
85. Pastrana E, Cheng LC, Doetsch F. Simultaneous prospective purification of adult subventricular zone neural stem cells and their progeny. Proc Natl Acad Sci USA 2009; 106: 6387-6392.
86. Aguirre A, Rubio ME, Gallo V. Notch and EGFR pathway interaction regulates neural stem cell number and self-renewal. Nature 2010; 467: 323-327.
87. Gonzalez-Perez O, Alvarez-Buylla A. Oligodendrogenesis in the subventricular zone and the role of epidermal growth factor. Brain Res Rev 2011; 67: 147-156.
88. Galvez-Contreras AY, Quinones-Hinojosa A, Gonzalez-Perez O. The role of EGFR and ErbB family related proteins in the oligodendrocyte specification in germinal niches of the adult mammalian brain. Front Cell Neurosci 2013; 7: 258.
89. Gomez-Gaviro MV, Scott CE, Sesay AK, Matheu A, Booth S, Galichet C et al. Betacellulin promotes cell proliferation in the neural stem cell niche and stimulates neurogenesis. Proc Natl Acad Sci USA 2012; 109: 1317-1322.
90. Lecona E, Fernandez-Capetillo O. Replication stress and cancer: it takes two to tango. Exp Cell Res 2014; 329: 26-34.
91. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H et al. Amplification and overexpression of the EGF receptor gene in primary human glioblastomas. J Cell Sci Suppl 1985; 3: 161-172.
92. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987; 84: 6899-6903.
93. Jeuken J, Sijben A, Alenda C, Rijntjes J, Dekkers M, Boots-Sprenger S et al. Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol 2009; 19: 661-671.
94. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991; 51: 2164-2172.
95. Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 2006; 3: e485.
96. Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 1990; 87: 8602-8606.
97. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992; 89: 2965-2969.
98. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails. Proc Natl Acad Sci USA 1992; 89: 4309-4313.
99. Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Sci Signal 2009; 2: re6.
100. Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 2007; 104: 12867-12872.
101. Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA et al. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 2009; 11: 442.
102. Zeineldin R, Ning Y, Hudson LG. The constitutive activity of epidermal growth factor receptor vIII leads to activation and differential trafficking of wild-type epidermal growth factor receptor and erbB2. J Histochem Cytochem 2010; 58: 529-541.
103. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996; 56: 5079-5086.
104. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000; 60: 1383-1387.
105. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001; 8: 83-96.
106. Pines G, Huang PH, Zwang Y, White FM, Yarden Y. EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene 2010; 29: 5850-60.
107. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
108. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
109. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
110. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006; 12: 7232-7241.
111. Teng YH, Tan WJ, Thike AA, Cheok PY, Tse GM, Wong NS et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res 2011; 13: R35.
112. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M et al. Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med 2005; 2: e313.
113. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
114. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007; 11: 217-227.
115. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008; 105: 2070-5.
116. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006; 20: 1496-1510.
117. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006; 9: 485-495.
118. Regales L, Balak MN, Gong Y, Politi K, Sawai A, Le C et al. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One 2007; 2: e810.
119. Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007; 12: 81-93.
120. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
121. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006; 12: 4283-4287.
122. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005; 37: 1315-1316.
123. Heinmoller P, Gross C, Beyser K, Schmidtgen C, Maass G, Pedrocchi M et al. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res 2003; 9: 5238-5243.
124. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
125. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
126. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14: 320-368.
127. Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metast Rev 2015; 34: 157-164.
128. Hechtman JF, Polydorides AD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med 2012; 136: 691-697.
129. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF III, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003; 100: 8933-8938.
130. Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S et al. Oncogenic ERBB3 mutations in human cancers. Cancer cell 2013; 23: 603-617.
131. Jeong EG, Soung YH, Lee JW, Lee SH, Nam SW, Lee JY et al. ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. Int J Cancer 2006; 119: 2986-2987.
132. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009; 41: 1127-1132.
133. Soung YH, Lee JW, Kim SY, Wang YP, Jo KH, Moon SW. Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer 2006; 118: 1426-1429.
134. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
135. Kurppa K, Elenius K. Mutated ERBB4: a novel drug target in metastatic melanoma? Pigment Cell Melanoma Res 2009; 22: 708-710.
136. Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. N Engl J Med 1980; 303: 878-880.
137. Schulze A, Lehmann K, Jefferies HB, McMahon M, Downward J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev 2001; 15: 981-994.
138. Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal 2005; 17: 1183-1193.
139. Kodama T, Ikeda E, Okada A, Ohtsuka T, Shimoda M, Shiomi T et al. ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am J Pathol 2004; 165: 1743-1753.
140. Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology (Bethesda, MD) 2010; 25: 85-101.
141. Berasain C, Avila MA. Amphiregulin. Semin Cell Dev Biol 2014; 28C: 31-41.
142. Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, Yu Y, Lee DC, Werb Z. Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development 2005; 132: 3923-3933.
143. Hsu D, Fukata M, Hernandez YG, Sotolongo JP, Goo T, Maki J et al. Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab Invest 2010; 90: 1295-1305.
144. Panupinthu N, Yu S, Zhang D, Zhang F, Gagea M, Lu Y et al. Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene 2013; 33: 2846-2856.
145. Sauer L, Gitenay D, Vo C, Baron VT. Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene 2010; 29: 2628-2637.
146. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237.
147. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3: 711-715.
148. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009; 15: 1010-1012.
149. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
150. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-132.
151. Visvader JE. Cells of origin in cancer. Nature 2011; 469: 314-322.
152. Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008; 27: 6120-6130.
153. Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P et al. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res 2009; 15: 2010-2021.
154. Chaffer CL, Weinberg RA. How does multistep tumorigenesis really proceed? Cancer Discov 2015; 5: 22-24.
155. Mazouzi A, Velimezi G, Loizou JI. DNA replication stress: causes, resolution and disease. Exp Cell Res 2014; 329: 85-93.
156. D'Uva G, Aharonov A, Lauriola M, Kain D, Yahalom-Ronen Y, Carvalho S et al. ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat Cell Biol 2015; 17: 627-638.
157. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO et al. Normal and neoplastic nonstem cells can spontaneously convert to a stemlike state. Proc Natl Acad Sci USA 2011; 108: 7950-7955.
158. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013; 154: 61-74.
159. Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F. Radiation-induced reprogramming of breast cancer cells. Stem cells 2012; 30: 833-844.
160. Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, Ziegler PK et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stemcell-like properties. Cell 2013; 152: 25-38.
161. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem 1979; 48: 193-216.
162. Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies. Breast 2013; 22(Suppl 2): S152-S155.
163. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683-2710.
164. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-173.
165. Kalman B, Szep E, Garzuly F, Post DE. Epidermal growth factor receptor as a therapeutic target in glioblastoma. Neuromol Med 2013; 15: 420-434.
166. Mazzoleni S, Politi LS, Pala M, Cominelli M, Franzin A, Sergi Sergi L et al. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res 2010; 70: 7500-7513.
167. Soeda A, Inagaki A, Oka N, Ikegame Y, Aoki H, Yoshimura S et al. Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J Biol Chem 2008; 283: 10958-10966.